GILEAD SCIENCES, INC. - 12 Feb 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Issuer symbol
KYTX
Transactions as of
12 Feb 2024
Net transactions value
+$20,020,000
Form type
4
Filing time
13 Feb 2024, 17:48:49 UTC
Previous filing
07 Feb 2024
Next filing
03 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Conversion of derivative security +3,216,119 3,216,119 12 Feb 2024 Direct F1, F2
transaction KYTX Common Stock Purchase $20,020,000 +910,000 +28% $22.00* 4,126,119 12 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Series A-2 Convertible Preferred Stock Conversion of derivative security $0 -6,890,744 -100% $0.000000* 0 12 Feb 2024 Common Stock 1,514,083 Direct F1, F2
transaction KYTX Series B Convertible Preferred Stock Conversion of derivative security $0 -7,746,139 -100% $0.000000* 0 12 Feb 2024 Common Stock 1,702,036 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GILEAD SCIENCES, INC. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.
F2 Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.